Yatrex Pharmaceuticals is a Luxembourg-based biotechnology company developing preclinical therapeutic candidates for ischemia-related injury in neurological and cardiovascular contexts.

The company’s strategy emphasizes strong biological rationale, differentiated modalities, and disciplined translational planning.